JAMA Cardiology Meta-analysis: Prasugrel the Best P2Y12 Inhibitor After PCI? Source TCTMD (June 5, 2026)
JAMA Cardiology Meta-analysis: Prasugrel the Best P2Y12 Inhibitor After PCI?
Source TCTMD (June 5, 2026)
Key Findings (15 RCTs, n=48,904):
Treatment Ranking
Efficacy
1. Prasugrel
2. Ticagrelor
3. Clopidogrel
Safety
1. Clopidogrel
2. Prasugrel
3. Ticagrelor
Clinical Message
* Supports previous findings from ISAR-REACT 5, where prasugrel outperformed ticagrelor in ACS without increased bleeding.
* Suggests prasugrel may offer the best efficacy–safety balance after PCI, particularly in younger ACS patients without prior stroke/TIA.
* Ticagrelor remains effective but was associated with:
* More major bleeding
* More intracranial hemorrhage
* More treatment discontinuation due to adverse events
Expert Perspective
Donald Cutlip, MD:
“Prasugrel should probably move up higher in our choice of antithrombotic therapy in acute coronary syndrome.”
Practical Take-Home
* ACS + PCI (no prior stroke/TIA): Prasugrel may be the preferred P2Y12 inhibitor.
* High bleeding risk or elderly/frail patients: individualized selection remains essential.
* Clopidogrel remains the safest but least effective option.
* Ticagrelor continues to be guideline-recommended but may no longer be viewed as the default potent P2Y12 inhibitor when prasugrel is suitable.
https://www.tctmd.com/news/meta-analysis-prasugrel-best-p2y12-inhibitor-after-pci
